|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.11/-0.59
|
企业价值
299.42M
|
资产负债 |
每股账面净值
0.78
|
现金流量 |
现金流量率
--
|
损益表 |
收益
299.49M
|
每股收益
0.56
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/28 04:36 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generatesmaximum revenue from the Consumer and Research Services segment. |